BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lin C, Kao J. Perspectives and control of hepatitis B virus infection in Taiwan. Journal of the Formosan Medical Association 2015;114:901-9. [DOI: 10.1016/j.jfma.2015.06.003] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Chen CH, Hsieh HH, Wu TY. Real-world prevalence of hepatitis B virus reactivation in cancer patients in Taiwan. J Oncol Pharm Pract 2021;27:63-70. [PMID: 32264743 DOI: 10.1177/1078155220913095] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Su TH, Kao JH. Response to Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Liver Int 2017;37:310-1. [PMID: 28070982 DOI: 10.1111/liv.13315] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Liu CC, Lu CL, Notobroto HB, Tsai CC, Wen PH, Li CY. Individual and neighborhood socioeconomic status in the prediction of liver transplantation among patients with liver disease: A population-based cohort study in Taiwan. Medicine (Baltimore) 2019;98:e14849. [PMID: 30882681 DOI: 10.1097/MD.0000000000014849] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
4 Tai C, Wu J, Chen H, Ni Y, Hsu H, Chang M. The Impact of Hepatitis B Vaccine Failure on Long-term Natural Course of Chronic Hepatitis B Virus Infection in Hepatitis B e Antigen–Seropositive Children. The Journal of Infectious Diseases 2017;216:662-9. [DOI: 10.1093/infdis/jix339] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
5 Bousali M, Papatheodoridis G, Paraskevis D, Karamitros T. Hepatitis B Virus DNA Integration, Chronic Infections and Hepatocellular Carcinoma. Microorganisms 2021;9:1787. [PMID: 34442866 DOI: 10.3390/microorganisms9081787] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Shi Y, Wang J, Wang Y, Wang A, Guo H, Wei F, Mehta SR, Espitia S, Smith DM, Liu L, Zhang Y, Chen D. A novel mutant 10Ala/Arg together with mutant 144Ser/Arg of hepatitis B virus X protein involved in hepatitis B virus-related hepatocarcinogenesis in HepG2 cell lines. Cancer Lett 2016;371:285-91. [PMID: 26706415 DOI: 10.1016/j.canlet.2015.12.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
7 Lin CL, Kao JH. New perspectives of biomarkers for the management of chronic hepatitis B. Clin Mol Hepatol. 2016;22:423-431. [PMID: 28081591 DOI: 10.3350/cmh.2016.0069] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 6.3] [Reference Citation Analysis]
8 Su TH, Kao JH. Unmet Needs in Clinical and Basic Hepatitis B Virus Research. J Infect Dis 2017;216:S750-6. [PMID: 29156048 DOI: 10.1093/infdis/jix382] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
9 Lin T, Yen H, Chiang J, Sun M, Chang H, Huang S. The use of Chinese herbal medicine as an adjuvant therapy to reduce incidence of chronic hepatitis in colon cancer patients: A Taiwanese population-based cohort study. Journal of Ethnopharmacology 2017;202:225-33. [DOI: 10.1016/j.jep.2017.03.027] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
10 Wang CC, Kao JH. How have the recent advances in antiviral therapy impacted the management of virus-related hepatocellular carcinoma? Expert Opin Pharmacother 2016;17:911-9. [PMID: 26831361 DOI: 10.1517/14656566.2016.1149165] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
11 Yao CC, Hung CH, Hu TH, Lu SN, Wang JH, Lee CM, Chen CH. Incidence and predictors of HBV relapse after cessation of nucleoside analogues in HBeAg-negative patients with HBsAg ≤ 200 IU/mL. Sci Rep 2017;7:1839. [PMID: 28500322 DOI: 10.1038/s41598-017-02010-w] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
12 Yang HC, Kao JH. Towards elimination of viral hepatitis in Taiwan by 2025: In memory of Professor Ding-Shinn Chen (1943-2020). J Formos Med Assoc 2020;119:1247-8. [PMID: 32654867 DOI: 10.1016/j.jfma.2020.07.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Tseng T, Kao J. HBV markers for HCC prediction: Three heads are better than two? Journal of Hepatology 2017;67:203-4. [DOI: 10.1016/j.jhep.2017.03.024] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
14 Tseng T, Liu C, Su T, Yang W, Chen C, Yang H, Kuo SF, Liu C, Chen P, Chen D, Kao J. Fibrosis-4 index predicts cirrhosis risk and liver-related mortality in 2075 patients with chronic HBV infection. Aliment Pharmacol Ther 2018;47:1480-9. [DOI: 10.1111/apt.14619] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
15 Nfor ON, Wu MF, Debnath T, Lee CT, Lee W, Liu WH, Tantoh DM, Hsu SY, Liaw YP. Hepatitis B virus infection in Taiwan: The role of NTCP rs2296651 variant in relation to sex. J Viral Hepat 2018;25:1116-20. [PMID: 29660219 DOI: 10.1111/jvh.12912] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
16 Lin CL, Kao JH. Hepatitis B: Immunization and Impact on Natural History and Cancer Incidence. Gastroenterol Clin North Am. 2020;49:201-214. [PMID: 32389359 DOI: 10.1016/j.gtc.2020.01.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
17 Lin CL, Tseng KC, Chen KY, Liao LY, Kao JH. Factors predicting outcomes of hepatitis B-related cirrhosis patients with long-term antiviral therapy. J Formos Med Assoc 2020;119:1483-9. [PMID: 32653388 DOI: 10.1016/j.jfma.2020.07.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
18 Inoue T, Tanaka Y. The Role of Hepatitis B Core-Related Antigen. Genes (Basel) 2019;10:E357. [PMID: 31075974 DOI: 10.3390/genes10050357] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
19 Cox AL, El-Sayed MH, Kao JH, Lazarus JV, Lemoine M, Lok AS, Zoulim F. Progress towards elimination goals for viral hepatitis. Nat Rev Gastroenterol Hepatol 2020;17:533-42. [PMID: 32704164 DOI: 10.1038/s41575-020-0332-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 9.0] [Reference Citation Analysis]
20 Kang YK, Meng FC. Acute fulminant hepatitis associated with osimertinib administration in a lung cancer patient with chronic hepatitis B: The first mortality case report. Thorac Cancer 2022. [PMID: 35146920 DOI: 10.1111/1759-7714.14346] [Reference Citation Analysis]
21 Jang TY, Wei YJ, Liu TW, Yeh ML, Liu SF, Hsu CT, Hsu PY, Lin YH, Liang PC, Hsieh MH, Ko YM, Tsai YS, Chen KY, Lin CC, Tsai PC, Wang SC, Huang CI, Lin ZY, Chen SC, Chuang WL, Huang JF, Dai CY, Huang CF, Yu ML. Role of hepatitis D virus infection in development of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleotide/nucleoside analogues. Sci Rep 2021;11:8184. [PMID: 33854160 DOI: 10.1038/s41598-021-87679-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Wang CC, Tzeng IS, Su WC, Li CH, Lin HH, Yang CC, Kao JH. The association of vitamin D with hepatitis B virus replication: Bystander rather than offender. J Formos Med Assoc 2020;119:1634-41. [PMID: 31932201 DOI: 10.1016/j.jfma.2019.12.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
23 Yang S, Ding C, Cui Y, Wu J, Yu C, Chen P, Xu K, Deng M, Li Y, Liu J, Yin P, Ren W, Qiu Y, Cao Q, Zhou Y, Yao J, Ruan B, Ren J, Li L. Prevalence and influencing factors of hepatitis B among a rural residential population in Zhejiang Province, China: a cross-sectional study. BMJ Open 2017;7:e014947. [PMID: 28373257 DOI: 10.1136/bmjopen-2016-014947] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
24 Lin CL, Kao JH. Natural history of acute and chronic hepatitis B: The role of HBV genotypes and mutants. Best Pract Res Clin Gastroenterol. 2017;31:249-255. [PMID: 28774406 DOI: 10.1016/j.bpg.2017.04.010] [Cited by in Crossref: 62] [Cited by in F6Publishing: 60] [Article Influence: 12.4] [Reference Citation Analysis]
25 Lin CL, Yang HC, Kao JH. Hepatitis B virus: new therapeutic perspectives. Liver Int. 2016;36 Suppl 1:85-92. [PMID: 26725903 DOI: 10.1111/liv.13003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
26 Tseng TC, Liu CJ, Su TH, Yang WT, Chen CL, Yang HC, Wang CC, Kuo SF, Liu CH, Chen PJ, Chen DS, Kao JH. Fibrosis-4 Index Helps Identify HBV Carriers With the Lowest Risk of Hepatocellular Carcinoma. Am J Gastroenterol. 2017;112:1564-1574. [PMID: 28853728 DOI: 10.1038/ajg.2017.254] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
27 Su TH, Hu TH, Chen CY, Huang YH, Chuang WL, Lin CC, Wang CC, Su WW, Chen MY, Peng CY, Chien RN, Huang YW, Wang HY, Lin CL, Yang SS, Chen TM, Mo LR, Hsu SJ, Tseng KC, Hsieh TY, Suk FM, Hu CT, Bair MJ, Liang CC, Lei YC, Tseng TC, Chen CL, Kao JH; C-TEAM study group and the Taiwan Liver Diseases Consortium. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Liver Int. 2016;36:1755-1764. [PMID: 27634134 DOI: 10.1111/liv.13253] [Cited by in Crossref: 108] [Cited by in F6Publishing: 100] [Article Influence: 18.0] [Reference Citation Analysis]
28 Wang CR, Tsai HW. Human hepatitis viruses-associated cutaneous and systemic vasculitis. World J Gastroenterol 2021; 27(1): 19-36 [PMID: 33505148 DOI: 10.3748/wjg.v27.i1.19] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
29 Clemente MG, Vajro P. An update on the strategies used for the treatment of chronic hepatitis B in children. Expert Rev Gastroenterol Hepatol 2016;10:649-58. [PMID: 26752166 DOI: 10.1586/17474124.2016.1139450] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
30 Wang CR, Tsai HW. Autoimmune liver diseases in systemic rheumatic diseases. World J Gastroenterol 2022; 28(23): 2527-2545 [DOI: 10.3748/wjg.v28.i23.2527] [Reference Citation Analysis]
31 Tseng TC, Kao JH. Elimination of Hepatitis B: Is It a Mission Possible? BMC Med 2017;15:53. [PMID: 28292309 DOI: 10.1186/s12916-017-0820-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
32 Lin CL, Kao JH. Prevention of mother-to-child transmission: the key of hepatitis B virus elimination. Hepatol Int 2018;12:94-6. [PMID: 29619622 DOI: 10.1007/s12072-018-9863-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
33 Yang YW, Chen CC, Yang CY, Lee CY, Yang HC, Chiang BL, Chuang YH, Wu TE, Lai HS, Tsai MK. Dynamics of cellular immune responses in recipients of renal allografts positive for hepatitis B surface antigen. J Formos Med Assoc 2021:S0929-6646(21)00338-7. [PMID: 34294497 DOI: 10.1016/j.jfma.2021.07.008] [Reference Citation Analysis]
34 Yao Z, Liao W, Ho C, Chen K, Shih J, Chen J, Lin Z, Lin C, Yang JC, Yu C. Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non–small-cell lung cancer patients. European Journal of Cancer 2019;117:107-15. [DOI: 10.1016/j.ejca.2019.05.032] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
35 Inoue T, Tanaka Y. Novel biomarkers for the management of chronic hepatitis B. Clin Mol Hepatol 2020;26:261-79. [PMID: 32536045 DOI: 10.3350/cmh.2020.0032] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
36 Yang HC, Kao JH. Looking into the crystal ball: biomarkers for outcomes of HBV infection. Hepatol Int 2016;10:99-101. [PMID: 26732689 DOI: 10.1007/s12072-015-9698-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
37 Tseng TC, Shih YF, Liu CJ. A simple non-invasive test for ruling out cirrhosis in chronic hepatitis B. Lancet Gastroenterol Hepatol 2019;4:495-6. [PMID: 30975476 DOI: 10.1016/S2468-1253(19)30118-9] [Reference Citation Analysis]
38 Lin CL, Kao JH. Hepatitis B reactivation in patients receiving immunosuppressive therapy: a hidden menace. Hepatol Int 2017;11:31-3. [PMID: 28058576 DOI: 10.1007/s12072-016-9782-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
39 Su T, Yang H, Tseng T, Liou J, Liu C, Chen C, Chen P, Chen D, Liu C, Kao J. Distinct Relapse Rates and Risk Predictors After Discontinuing Tenofovir and Entecavir Therapy. The Journal of Infectious Diseases 2018;217:1193-201. [DOI: 10.1093/infdis/jix690] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 8.5] [Reference Citation Analysis]
40 Wang ST, Tseng CW, Hsu CW, Tung CH, Huang KY, Lu MC, Lai NS. Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib. Int J Rheum Dis 2021;24:1362-9. [PMID: 34506078 DOI: 10.1111/1756-185X.14217] [Reference Citation Analysis]
41 Kao JH, Asselah T, Dou XG, Hamed K. Telbivudine therapy for chronic hepatitis B: A journey to identify super-responders and to optimize treatment using the roadmap model. J Gastroenterol Hepatol 2017;32:73-81. [PMID: 27515408 DOI: 10.1111/jgh.13512] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
42 Yanag Y, Du D, Jin L, Tian Z, Li Q, Yi R, Qiu T, Yang D, He Y, Liu J, Chen T, Zhao Y. A molecular epidemiology study investigating familial clustering of hepatitis B virus infection in families with unfavorable prognoses in Northwest China. J Med Virol 2017;89:1427-34. [PMID: 28198546 DOI: 10.1002/jmv.24783] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
43 Hayashi K, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Tachi Y, Ishikawa T, Katano Y, Yoshioka K, Toyoda H, Kumada T, Goto H, Hirooka Y. Clinical characteristics and molecular analysis of hepatitis B virus reactivation in hepatitis B surface antigen-negative patients during or after immunosuppressive or cytotoxic chemotherapy. J Gastroenterol 2016;51:1081-9. [PMID: 26943169 DOI: 10.1007/s00535-016-1187-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
44 Kao J. Hepatitis B: From control to cure. Journal of the Formosan Medical Association 2018;117:868-70. [DOI: 10.1016/j.jfma.2018.08.020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
45 Haga Y, Kanda T, Nakamura M, Nakamoto S, Sasaki R, Takahashi K, Wu S, Yokosuka O. Overexpression of c-Jun contributes to sorafenib resistance in human hepatoma cell lines. PLoS One 2017;12:e0174153. [PMID: 28323861 DOI: 10.1371/journal.pone.0174153] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
46 Chen H, Su T, Tseng T, Yang W, Chen T, Chen P, Chen D, Kao J, Liu C. Impact of occult hepatitis B on the clinical outcomes of patients with chronic hepatitis C virus infection: A 10-year follow-up. Journal of the Formosan Medical Association 2017;116:697-704. [DOI: 10.1016/j.jfma.2016.11.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
47 Kao CN, Su TH, Kao JH. Letter: HBsAg kinetics-guided interferon therapy for chronic hepatitis D. Aliment Pharmacol Ther 2017;45:480-1. [PMID: 28043091 DOI: 10.1111/apt.13872] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
48 Huang YS, Sun HY, Chang SY, Chuang YC, Cheng A, Huang SH, Huang YC, Chen GJ, Lin KY, Su YC, Liu WC, Hung CC. Long-term virological and serologic responses of chronic hepatitis B virus infection to tenofovir disoproxil fumarate-containing regimens in patients with HIV and hepatitis B coinfection. Hepatol Int 2019;13:431-9. [PMID: 31177505 DOI: 10.1007/s12072-019-09953-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
49 Lin CL, Kao JH. Review article: novel therapies for hepatitis B virus cure - advances and perspectives. Aliment Pharmacol Ther. 2016;44:213-222. [PMID: 27302653 DOI: 10.1111/apt.13694] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 6.2] [Reference Citation Analysis]
50 Wang CC, Tseng KC, Hsieh TY, Tseng TC, Lin HH, Kao JH. Assessing the Durability of Entecavir-Treated Hepatitis B Using Quantitative HBsAg. Am J Gastroenterol. 2016;111:1286-1294. [PMID: 27045923 DOI: 10.1038/ajg.2016.109] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 7.2] [Reference Citation Analysis]
51 Baudi I, Inoue T, Tanaka Y. Novel Biomarkers of Hepatitis B and Hepatocellular Carcinoma: Clinical Significance of HBcrAg and M2BPGi. Int J Mol Sci. 2020;21. [PMID: 32023902 DOI: 10.3390/ijms21030949] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
52 Wang PC, Wei TY, Tseng TC, Lin HH, Wang CC. Cirrhosis has no impact on therapeutic responses of entecavir for chronic hepatitis B. Eur J Gastroenterol Hepatol 2017;29:946-50. [PMID: 28538267 DOI: 10.1097/MEG.0000000000000897] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]